In the HR model of xenotransplantation in patients with ALL, pharmacological inhibition of CK2 can restore the DNA-binding affinity and tumor inhibitory activity of IKAROS and cause leukemia cytotoxicity, demonstrating the possibility of using CK2 inhibitors as therapeutic approaches for HR pediatric leukemia [122,162]. This evidence concerns the gene IKZF1 and leukemia.